Business Description
Aker BioMarine ASA
ISIN : NO0010886625
Share Class Description:
OSL:AKBM: Ordinary SharesCompare
Compare
Traded in other countries / regions
AKBM.NorwayAKBMo.Sweden1PG.Germany IPO Date
2020-07-06Description
Aker BioMarine ASA is a supplier of krill-derived products, with a fully owned supply chain. The operations of the company span from harvesting krill in Antarctica with vessels owned by the company including distribution from Uruguay, and further processing of the krill into oil products in the United States. The segments of the company include 1) The Ingredients segment involves offshore harvesting and production, logistical operations, and onshore manufacturing and sales of krill-derived products. 2) The Brands segment focuses on human consumer goods, with Lang Pharma Nutrition (Lang) and Epion as its two main components. Lang produces and distributes private-label vitamins and supplements to retailers in the U.S. market and Epion is Aker BioMarine's consumer brand company.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.1 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.79 | |||||
| Debt-to-EBITDA | 3.35 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.15 | |||||
| Beneish M-Score | -0.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.8 | |||||
| 3-Year EBITDA Growth Rate | -7.5 | |||||
| 3-Year EPS without NRI Growth Rate | -27 | |||||
| 3-Year FCF Growth Rate | 69.8 | |||||
| 3-Year Book Growth Rate | 5.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | -5.8 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 83.29 | |||||
| 9-Day RSI | 76.24 | |||||
| 14-Day RSI | 68.35 | |||||
| 6-1 Month Momentum % | -34.39 | |||||
| 12-1 Month Momentum % | 21.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.68 | |||||
| Quick Ratio | 1.87 | |||||
| Cash Ratio | 0.25 | |||||
| Days Inventory | 224.65 | |||||
| Days Sales Outstanding | 64.3 | |||||
| Days Payable | 59.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 28.77 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 30.88 | |||||
| Operating Margin % | -0.31 | |||||
| Net Margin % | 56.76 | |||||
| FCF Margin % | 4.67 | |||||
| ROE % | 63.48 | |||||
| ROA % | 28.04 | |||||
| ROIC % | -0.03 | |||||
| ROC (Joel Greenblatt) % | -0.66 | |||||
| ROCE % | -0.5 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 2.34 | |||||
| Forward PE Ratio | 34.52 | |||||
| PE Ratio without NRI | 588.24 | |||||
| Price-to-Owner-Earnings | 1.66 | |||||
| PEG Ratio | 56.02 | |||||
| PS Ratio | 1.27 | |||||
| PB Ratio | 2.61 | |||||
| Price-to-Tangible-Book | 5.91 | |||||
| Price-to-Free-Cash-Flow | 26.54 | |||||
| Price-to-Operating-Cash-Flow | 8.77 | |||||
| EV-to-EBIT | -211.62 | |||||
| EV-to-Forward-EBIT | 16.49 | |||||
| EV-to-EBITDA | 14.19 | |||||
| EV-to-Forward-EBITDA | 13.01 | |||||
| EV-to-Revenue | 1.74 | |||||
| EV-to-Forward-Revenue | 2.49 | |||||
| EV-to-FCF | 31.85 | |||||
| Price-to-Peter-Lynch-Fair-Value | 38.22 | |||||
| Price-to-Graham-Number | 12.42 | |||||
| Price-to-Net-Current-Asset-Value | 113.21 | |||||
| Earnings Yield (Greenblatt) % | -0.47 | |||||
| FCF Yield % | 3.42 | |||||
| Forward Rate of Return (Yacktman) % | 7.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aker BioMarine ASA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 3,858.076 | ||
| EPS (TTM) (kr) | 25.699 | ||
| Beta | 0.74 | ||
| Volatility % | 30.45 | ||
| 14-Day RSI | 68.35 | ||
| 14-Day ATR (kr) | 2.718367 | ||
| 20-Day SMA (kr) | 52.01 | ||
| 12-1 Month Momentum % | 21.46 | ||
| 52-Week Range (kr) | 39.55 - 109.8 | ||
| Shares Outstanding (Mil) | 87.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aker BioMarine ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aker BioMarine ASA Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aker BioMarine ASA Frequently Asked Questions
What is Aker BioMarine ASA(OSL:AKBM)'s stock price today?
The current price of OSL:AKBM is kr60.00. The 52 week high of OSL:AKBM is kr109.80 and 52 week low is kr39.55.
When is next earnings date of Aker BioMarine ASA(OSL:AKBM)?
The next earnings date of Aker BioMarine ASA(OSL:AKBM) is 2025-02-14.
Does Aker BioMarine ASA(OSL:AKBM) pay dividends? If so, how much?
Aker BioMarine ASA(OSL:AKBM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers